Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2008

01-01-2008 | Clinical Trial

Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen

Authors: Mahmoud R. Khoshnoud, Tommy Fornander, Hemming Johansson, Lars-Erik Rutqvist

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Login to get access

Abstract

Purpose

Recent studies on the pattern of gene expression in estrogen receptor positive and negative tumours have revealed profound differences according to receptor status. However, it remains unclear if these differences reflect phenotypic traits in addition to sensitivity to endocrine therapy. This paper describes the long-term pattern of disease recurrence among ca. 2,600 pre- and post-menopausal patients with primary breast cancer according to estrogen receptor status.

Material and methods

The study was based on patients with an operable, invasive breast cancer entered in one of three controlled clinical trials conducted by the Stockholm Breast Cancer Group. We selected those 2,562 patients who had been randomly allocated between adjuvant tamoxifen and no adjuvant systemic therapy. These patients had a known estrogen receptor status.

Result

Tamoxifen reduced locoregional (8.8% vs. 12.4%, hazard ratio (HR), 0.66; 95% CI, 0.52–0.83; P = 0.001, distant recurrences (17.2% vs. 20.2%, HR, 0.81; CI, 0.68–0.97; P = 0.018, as well as breast cancer death (18.7% vs. 23.7%, HR, 0.78; CI, 0.67–0.92; P = 0.002). Among patients not allocated to tamoxifen there was no significant differences in term of neither locoregional (12.4% vs. 12.4%, HR, 1; CI, 0.72–1.41; P = 0.98), nor distant metastases (18.5% vs. 20.7%, HR, 1.11;CI, 0.85–1.45; P = 0.46) according to ER status. The pattern of metastases was not different in ER positive comparison with ER negative.

Conclusion

The results showed that the mentioned substantial differences in terms of gene expression appeared mainly to be related to endocrine sensitivity and not to metastatic potential. However, a slight advantage during the first five years for the ER positive versus ER negative patients in terms of cumulative incidence of events, suggested that ER negativity in some cases is correlated with an increased tumour growth rate.
Literature
1.
go back to reference Oxford overview, Chemotherapy and hormonal therapy for early breast cancer:effect on recurrence and 15-year survival in an overview of the randomised trials by Early breast cancer trialists’ collaborative group (EBCTCG). December 2004 Oxford overview, Chemotherapy and hormonal therapy for early breast cancer:effect on recurrence and 15-year survival in an overview of the randomised trials by Early breast cancer trialists’ collaborative group (EBCTCG). December 2004
2.
go back to reference Rutqvist LE et al (1987) The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10(3):255–266PubMedCrossRef Rutqvist LE et al (1987) The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10(3):255–266PubMedCrossRef
3.
go back to reference Rutqvist LE et al (1989) The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 7(1(EBCTCG), E.b.c.t.c.g., Chemotherapy and hormonal therapy for early breast cancer: effects on recurrence and 15-year survival in an overview of the r 0):1474–1484 Rutqvist LE et al (1989) The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 7(1(EBCTCG), E.b.c.t.c.g., Chemotherapy and hormonal therapy for early breast cancer: effects on recurrence and 15-year survival in an overview of the r 0):1474–1484
4.
go back to reference Stockholm Breast Cancer Study Group (1992) Stockholm adjuvant breast cancer trials 5–8, Stockholm, Sweden, Oncologic Centre Stockholm Breast Cancer Study Group (1992) Stockholm adjuvant breast cancer trials 5–8, Stockholm, Sweden, Oncologic Centre
5.
go back to reference Wrange O et al (1976) Isoelectric focusing of estradiol receptor protein from human mammary carcinoma – a comparison to sucrose gradient analysis. Eur J Cancer 12(9):695–700PubMed Wrange O et al (1976) Isoelectric focusing of estradiol receptor protein from human mammary carcinoma – a comparison to sucrose gradient analysis. Eur J Cancer 12(9):695–700PubMed
6.
go back to reference Wrange O, Nordenskjold B, Gustafsson JA (1978) Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85(2):461–475PubMedCrossRef Wrange O, Nordenskjold B, Gustafsson JA (1978) Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85(2):461–475PubMedCrossRef
7.
go back to reference Ferno M, Borg A, Norgren A (1983) A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3(4):243–246PubMed Ferno M, Borg A, Norgren A (1983) A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3(4):243–246PubMed
8.
go back to reference Ferno M, Borg A, Sellberg G (1986) Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25(3):171–175PubMed Ferno M, Borg A, Sellberg G (1986) Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25(3):171–175PubMed
9.
go back to reference Burton K (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of DNA. Biochem 62:315–322 Burton K (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of DNA. Biochem 62:315–322
10.
go back to reference Marubini E, Valsecchi MG (1995) Analysing survival data from clinical trials and observational studies. John Willey and sons. capital 10:331–361 Marubini E, Valsecchi MG (1995) Analysing survival data from clinical trials and observational studies. John Willey and sons. capital 10:331–361
11.
go back to reference Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346PubMedCrossRef Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346PubMedCrossRef
12.
go back to reference Knight WA et al (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37(12):4669–4671PubMed Knight WA et al (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37(12):4669–4671PubMed
13.
go back to reference Maynard PV et al (1978) Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38(11 Pt 2):4292–4295PubMed Maynard PV et al (1978) Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38(11 Pt 2):4292–4295PubMed
14.
go back to reference Crowe JP Jr et al (1991) Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 173(4):273–278PubMed Crowe JP Jr et al (1991) Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 173(4):273–278PubMed
15.
go back to reference Crowe JP et al (1982) Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2(2):171–176PubMedCrossRef Crowe JP et al (1982) Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2(2):171–176PubMedCrossRef
16.
go back to reference Logan LA et al (1982) The estrogen receptor test: a prognostic tool in primary breast cancer. Can J Surg 25(5):581–584PubMed Logan LA et al (1982) The estrogen receptor test: a prognostic tool in primary breast cancer. Can J Surg 25(5):581–584PubMed
17.
go back to reference Aamdal S et al (1984) Estrogen receptors and long-term prognosis in breast cancer. Cancer 53(11):2525–2529PubMedCrossRef Aamdal S et al (1984) Estrogen receptors and long-term prognosis in breast cancer. Cancer 53(11):2525–2529PubMedCrossRef
18.
go back to reference Parl FF et al (1984) Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54(10):2237–2242PubMedCrossRef Parl FF et al (1984) Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54(10):2237–2242PubMedCrossRef
19.
go back to reference Donegan WL (1992) Prognostic factors. Stage and receptor status in breast cancer. Cancer 70(6 Suppl):1755–1764PubMedCrossRef Donegan WL (1992) Prognostic factors. Stage and receptor status in breast cancer. Cancer 70(6 Suppl):1755–1764PubMedCrossRef
20.
go back to reference Raemaekers JM et al (1985) Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 6(2):123–130PubMedCrossRef Raemaekers JM et al (1985) Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 6(2):123–130PubMedCrossRef
21.
go back to reference Todd JH et al (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56(4):489–492PubMed Todd JH et al (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56(4):489–492PubMed
22.
go back to reference Clark GM et al (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320(10):627–633PubMedCrossRef Clark GM et al (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320(10):627–633PubMedCrossRef
23.
go back to reference Osborne CK et al (2001) Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7(12 Suppl):4338s–4342s discussion 4411s–4412sPubMed Osborne CK et al (2001) Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7(12 Suppl):4338s–4342s discussion 4411s–4412sPubMed
24.
go back to reference Skog S et al (2004) Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumour Biol 25(1–2):41–47PubMedCrossRef Skog S et al (2004) Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumour Biol 25(1–2):41–47PubMedCrossRef
25.
go back to reference Gruvberger S et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61(16):5979–5984PubMed Gruvberger S et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61(16):5979–5984PubMed
26.
go back to reference Dickson RB, Lippman ME (1995) Drug and hormonal resistance in breast cancer, cellular and molecular mechanism. Ellis Horwood Ltd., New York Dickson RB, Lippman ME (1995) Drug and hormonal resistance in breast cancer, cellular and molecular mechanism. Ellis Horwood Ltd., New York
27.
go back to reference Stal O et al (1994) Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16(2):160–168PubMedCrossRef Stal O et al (1994) Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16(2):160–168PubMedCrossRef
28.
go back to reference Rosanelli GP et al (1995) Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters. Anticancer Res 15(2):581–586PubMed Rosanelli GP et al (1995) Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters. Anticancer Res 15(2):581–586PubMed
29.
go back to reference Corte MD et al (2005) Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance. Breast Cancer Res Treat 90(1):33–40PubMedCrossRef Corte MD et al (2005) Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance. Breast Cancer Res Treat 90(1):33–40PubMedCrossRef
30.
go back to reference Rodriguez J et al (2005) Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int J Biol Markers 20(2):103–111PubMed Rodriguez J et al (2005) Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int J Biol Markers 20(2):103–111PubMed
31.
go back to reference Aaltonen M et al (1995) Prognostic value of cathepsin-D expression in female breast cancer. Anticancer Res 15(3):1033–1037PubMed Aaltonen M et al (1995) Prognostic value of cathepsin-D expression in female breast cancer. Anticancer Res 15(3):1033–1037PubMed
Metadata
Title
Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen
Authors
Mahmoud R. Khoshnoud
Tommy Fornander
Hemming Johansson
Lars-Erik Rutqvist
Publication date
01-01-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9520-0

Other articles of this Issue 1/2008

Breast Cancer Research and Treatment 1/2008 Go to the issue

Preclinical Study/Clinical Trial/Epidmiology/Invited Commentary

Screening for ATM sequence alterations in African-American women diagnosed with breast cancer

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

Quantitative detection of circulating epithelial cells by Q-RT-PCR

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine